#United States #Orlando #Neuromodulation #Saluda Medical #EVA

Saluda Medical Unveils New Insights on Chronic Pain Treatment at 2025 NANS Meeting

Saluda Medical, a renowned innovator in neuromodulation technologies, made a significant impact at the 2025 North American Neuromodulation Society (NANS) Annual Meeting, held from January 30 to February 1 in Orlando, Florida. With eleven abstracts and four oral presentations, the company showcased compelling clinical data that promises to enhance the treatment landscape for patients suffering from chronic neurological conditions.

Key Highlights of the Presentation

Among the standout presentations was the inaugural human data on EVA™, Saluda's automated spinal cord stimulation (SCS) programming platform. This innovative platform, recently approved by the FDA, aims to transition SCS programming from subjective assessments to objective measurements.

Dr. Ajay Anthony presented findings that revealed striking results from a clinical study involving the EVA platform:

• - An impressive 94% of programming sessions resulted in successful closed-loop programs.
• - The median time required to create patient-specific automated programs was under 13 minutes.
• - Feedback from patients showed that over 90% felt satisfied or very satisfied with their experience using EVA.

The meeting also highlighted two oral presentations that received the prestigious “Top Oral Abstract” award. These presentations focused on the relationship between evoked compound action potential (ECAP) biomarkers and pain outcomes, underscoring how advanced neurophysiological measurements can influence SCS therapy.

Exceptional Real-World Findings

One of the hallmark studies presented, led by Dr. Jason Pope, explored real-world data from the largest SCS study involving 220 patients. This study demonstrated statistically significant enhancements in pain levels across all categories examined, including conditions such as Failed Back Surgery Syndrome and Complex Regional Pain Syndrome. Observations noted a minimum two-point improvement on the MCID scale across various pain subgroups, a tremendous result that indicates the therapy's effectiveness in a real-world setting.

Dr. Harold Nijhuis also contributed by characterizing spinal cord neurophysiology using ECAP dose-controlled closed-loop SCS. Remarkably, his findings indicated significant differences in sensitivity between cervical and thoracic spinal regions, suggesting a need for precise dosing techniques for optimal patient outcomes.

Transforming Patient Care

Saluda Medical's President, Jim Schuermann, expressed pride in the progress made and the company's role in redefining the standards of care for SCS. He stated, "We believe the next generation of SCS is here, and it's founded on objective science, precision, and personalized therapy that will continue to elevate patient care."

Dr. Jason Pope echoed this sentiment, emphasizing the vital clarity gained from understanding the link between ECAP biomarkers and pain outcomes. He highlighted that this new approach not only tailors therapies to individual needs but also establishes predictive markers for better patient responses to treatments, which could lead to groundbreaking advancements in managing chronic pain.

Commitment to Innovation

The accolades received by the Evoke® System during the NANS Annual Meeting signify Saluda Medical's commitment to pushing the boundaries of neuromodulation research. By integrating real-world clinical evidence with automated technology, the company is empowering healthcare providers to offer more precise and effective therapeutic options, thereby improving the quality of life for those living with chronic pain conditions.

In conclusion, the advances showcased at the 2025 NANS Annual Meeting reflect Saluda Medical's unwavering dedication to innovating therapies that reimagine pain management. Through its pioneering efforts and rigorous clinical research, the company continues to stand at the forefront of neurotechnology, helping to revolutionize the treatment landscape for patients with chronic pain.